

the method described previously.<sup>24</sup>

**Muscarinic Cholinergic Receptor Binding** (<sup>3</sup>H]QNB). This assay was also carried out on male Olac rat brain by the method previously described.<sup>4</sup>

**Anticonflict Behavior.** The method used was as described by Tye et al.<sup>25</sup> and was based on that of Geller and Seifter.<sup>26</sup>

Male wistar rats, maintained on a 23-h food-deprivation schedule, but with water available ad libitum in the home cage, were trained in a standard rodent operant test chamber to press the left of two levers for food reward on a continuous reinforcement schedule. Once this had been mastered, the schedule of reinforcement was altered to a variable interval 30 s (VI<sub>30</sub>) with limits of 5 and 55 s.

The animals were then trained on the multiple schedule comprising three components.

**Component 1 (Reward).** Nine minutes where lever pressing was reinforced according to the VI<sub>30</sub> schedule. This period was signalled by illumination of the house light and each reinforced response by illumination of the food magazine light for 0.5 s.

**Component 2 (Timeout).** Three minutes during which lever pressing was not reinforced. This period was signalled by darkness.

**Component 3 (Conflict).** Three minutes during which every tenth response was reinforced (Fixed ratio 10) as well as punished (0.8 mA electric foot shock delivered through the grid floor for 0.5 s). This period was signalled by illumination of the house light and another three lights (one above each lever and one located centrally above the food magazine). As in the first component, reinforced responses were signalled by illumination of the magazine light for 0.5 s.

This sequence of three components was presented twice in the same order during the daily, 30-min test session. Animals were trained until stable rates of responding were achieved over several days. On test days the animals received the drug or vehicle, according to a predetermined randomized sequence, 60 min prior to behavioral testing. Differences in mean responses per min from control were analyzed by the Wilcoxon test and the statistical significance indicated where appropriate.

**Acknowledgment.** We thank Colin Smith and in particular Derek Clissold for development work on the synthesis of these compounds, David Steggles and John Fairhurst for the preparation of some of the final compounds, David Rackham, Sarah Morgan, Richard Eggleton, Peter Callow, and Julie Smith for the spectroscopic data, and Susan Wedley, Francesca Risius, and Linda Horsman

for the pharmacological assays. Elemental analyses were carried out at the Lilly Microanalytical Lab, Indianapolis, IN.

**Registry No.** 4, 122799-79-5; 5, 122799-80-8; 6, 79291-90-0; 7, 79291-78-4; 8, 79291-79-5; 9, 79291-94-4; 10, 79291-69-3; 11, 79291-75-1; 12, 79291-76-2; 13, 79291-77-3; 14, 122799-81-9; 15, 122821-42-5; 16, 79291-71-7; 17, 122821-43-6; 18, 79291-73-9; 19, 79291-74-0; 20, 79291-91-1; 21, 79291-72-8; 22, 79291-87-5; 23, 79291-88-6; 24, 79291-89-7; 25, 122799-82-0; 26, 79291-83-1; 27, 122799-83-1; 28, 79291-84-2; 29, 122799-84-2; 30, 79291-85-3; 31, 79291-81-9; 32, 122799-85-3; 33, 79291-86-4; 34, 122799-86-4; 35, 122799-87-5; 36, 79291-92-2; 37, 79291-93-3; 38, 122799-88-6; 39, 122799-89-7; 40, 122799-90-0; 41, 122799-91-1; 42, 79291-63-7; 42-HCl, 79291-64-8; 43, 122799-92-2; 44, 122799-93-3; 45, 122799-94-4; 46, 31037-02-2; 47, 21230-43-3; 48, 21230-50-2; 49, 90641-64-8; 50, 122799-95-5; 51, 122799-96-6; 52, 2121-23-5; 53, 122799-97-7; 54, 122799-98-8; 55, 122799-99-9; 56, 122800-00-4; 57, 16078-63-0; 58, 122800-01-5; 59, 34605-61-3; 60, 122821-44-7; 61, 74772-07-9; 62, 122800-02-6; 63, 74772-08-0; 64, 79291-38-6; 65, 79291-40-0; 66, 79291-43-3; 67, 79291-44-4; 68, 79291-45-5; 69, 122800-03-7; 70, 122800-04-8; 71, 79291-58-0; 72, 122800-05-9; 73, 79291-42-2; 74, 122800-06-0; 75, 79291-56-8; 76, 79291-46-6; 77, 79291-52-4; 78, 122800-07-1; 79, 79291-54-6; 80, 122800-08-2; 81, 79291-48-8; 82, 122800-09-3; 83, 79291-49-9; 84, 122800-10-6; 85, 79291-50-2; 86, 79291-47-7; 87, 122800-11-7; 88, 79291-41-1; 89, 79291-51-3; 90, 122800-12-8; 91, 122800-13-9; 92, 122800-14-0; 93, 122800-15-1; 94, 79291-60-4; 95, 122800-16-2; 96, 122800-17-3; 97, 122800-18-4; XIII (X = 7-F, R<sub>1</sub> = 2-Me), 122821-45-8; ethyl 3-aminopyrazole-4-carboxylate, 6994-25-8; 1-bromohexane, 111-25-1; 1,5-dimethyl-4-nitropyrazole-3-carboxylic acid, 3920-41-0; ethyl 4-nitro-1,5-dimethylpyrazole-3-carboxylate, 122800-19-5; 1,4-difluoro-2-nitrobenzene, 364-74-9; *N*-methylpiperazine, 109-01-3; 3-aminopyrazole-4-carbonitrile, 16617-46-2; 2-fluoronitrobenzene, 1493-27-2; 1,4-dichloro-2-nitrobenzene, 89-61-2; 1,2,4-trifluoro-5-nitrobenzene, 2105-61-5; 2,4-difluoro-1-nitrobenzene, 446-35-5; 1,3-dichloro-2-nitrobenzene, 601-88-7; 2,4-dichloro-1-nitrobenzene, 611-06-3; 1,2-dichloro-3-nitrobenzene, 3209-22-1; 1,2,4-trichloro-5-nitrobenzene, 89-69-0; 1,4-dibromo-2-nitrobenzene, 3460-18-2; 1-fluoro-4-iodo-2-nitrobenzene, 364-75-0; 2-fluoro-4-methyl-1-nitrobenzene, 446-34-4; 1-fluoro-2-nitro-4-(trifluoromethyl)benzene, 367-86-2; (4-fluoro-3-nitrophenyl)phenylmethane, 82571-93-5; 1-fluoro-4-(methylsulfonyl)-2-nitrobenzene, 453-72-5; (bromomethyl)cyclopropane, 7051-34-5; 4-amino-1,3-dimethylpyrazole-5-carbonitrile, 32183-14-5; piperazine, 110-85-0.

## Additions and Corrections

### 1987, Volume 30

**Christopher B. Chapleo,\* Peter L. Myers, Alan C. B. Smith, Ian F. Tulloch, and Donald S. Walter:** Substituted 1,3,4-Thiadiazoles with Anticonvulsant Activity. 3. Guanidines.

Page 951. The list of authors should be as follows: Christopher B. Chapleo,\* Peter L. Myers, Alan C. B. Smith, Ian F. Tulloch, Stephen Turner, and Donald S. Walter.

### 1988, Volume 31

**Andre Rosowsky,\* Henry Bader, Ronald A. Forsch, Richard G. Moran, and James H. Freisheim:** Methotrexate Analogues. 31. Meta and Ortho Isomers of Aminopterin, Compounds with a Double Bond in the Side Chain, and a Novel Analogue Modified at the  $\alpha$ -Carbon: Chemical and in Vitro Biological Studies.

Page 765. Right-hand column, line 7 and line 10, the

concentrations should read 15–25 nM and 30–40 nM, respectively, and not 15–25 and 30–40  $\mu$ M.

**L. G. Humber,\* E. Ferdinandi, C. A. Demerson, S. Ahmed, U. Shah, D. Mobilio, J. Sabatucci, B. De Lange, F. Labbadia, P. Hughes, J. DeVirgilio, G. Neuman, T. T. Chau, and B. M. Weichman:** Etodolac, a Novel Antiinflammatory Agent. The Syntheses and Biological Evaluation of Its Metabolites.

Page 1715. The last sentence in paragraph 2 should read: The derivatized metabolite isolated from human urine was identical with 34, isomer A, by HPLC and NMR comparisons.

**Rajeshwar D. Bindal and John A. Katzenellenbogen\*:** Bis(4-hydroxyphenyl)[2-(phenoxy sulfonyl)phenyl]methane: Isolation and Structure Elucidation of a Novel Estrogen from Commercial Preparations of Phenol Red (Phenolsulfonphthalein).

Page 1978. The correct spelling for the first author's name is Rajeshwar D. Bindal.